Traumatic brain injury induced temperature dysregulation: What is the role of β blockers?
Abbreviated Injury Scale
Adrenergic beta-Antagonists
/ therapeutic use
Atenolol
/ therapeutic use
Body Temperature
/ drug effects
Brain Injuries, Traumatic
/ complications
Female
Humans
Hyperthermia
/ etiology
Male
Metoprolol
/ therapeutic use
Middle Aged
Propensity Score
Propranolol
/ therapeutic use
Retrospective Studies
Treatment Outcome
Journal
The journal of trauma and acute care surgery
ISSN: 2163-0763
Titre abrégé: J Trauma Acute Care Surg
Pays: United States
ID NLM: 101570622
Informations de publication
Date de publication:
01 01 2021
01 01 2021
Historique:
entrez:
17
12
2020
pubmed:
18
12
2020
medline:
15
4
2021
Statut:
ppublish
Résumé
Traumatic brain injury (TBI) is associated with sympathetic discharge that leads to posttraumatic hyperthermia (PTH). Beta blockers (ββ) are known to counteract overactive sympathetic discharge. The aim of our study was to evaluate the effect of ββ on PTH in critically-ill TBI patients. We performed retrospective cohort analysis of the Medical Information Mart for Intensive Care database. We included all critically ill TBI patients with head Abbreviated Injury Scale (AIS) score of 3 or greater and other body region AIS score less than 2 who developed PTH (at least one febrile episode [T > 38.3°C] with negative microbiological cultures (blood, urine, and bronchoalveolar lavage). Patients on preinjury ββ were excluded. Patients were stratified into (ββ+) and (ββ-) groups. Propensity score matching was performed (1:1 ratio) controlling for patient demographics, injury parameters and other medications that influence temperature. Outcomes were the number of febrile episodes, maximum temperature, and the time interval between febrile episodes. Multivariate linear regression was performed. We analyzed 4,286 critically ill TBI patients. A matched cohort of 1,544 patients was obtained: 772 ββ + (metoprolol, 60%; propranolol, 25%; and atenolol, 15%) and 772 ββ-. Mean age was 63.4 ± 15.4 years, median head AIS score of 3 (3-4), and median Injury Severity Score of 10 (9-16). Patients in the ββ+ group had a lower number of febrile episodes (8 episodes vs. 12 episodes; p = 0.003), lower median maximum temperature (38.0°C vs. 38.5°C; p = 0.025), and a longer median time between febrile episodes (3 hours vs. 1 hour; p = 0.013). On linear regression, propranolol was found to be superior in terms of reducing the number of febrile episodes and the maximum temperature. However, there was no significant difference between the three ββ in terms of reducing the time interval between febrile episodes (p = 0.582). Beta blockers attenuate PTH by decreasing the frequency of febrile episodes, increasing the time interval between febrile episodes, and reducing the maximum rise in temperature. ββ may be a potential therapeutic modality in PTH. Therapeutic, level IV.
Sections du résumé
BACKGROUND
Traumatic brain injury (TBI) is associated with sympathetic discharge that leads to posttraumatic hyperthermia (PTH). Beta blockers (ββ) are known to counteract overactive sympathetic discharge. The aim of our study was to evaluate the effect of ββ on PTH in critically-ill TBI patients.
METHODS
We performed retrospective cohort analysis of the Medical Information Mart for Intensive Care database. We included all critically ill TBI patients with head Abbreviated Injury Scale (AIS) score of 3 or greater and other body region AIS score less than 2 who developed PTH (at least one febrile episode [T > 38.3°C] with negative microbiological cultures (blood, urine, and bronchoalveolar lavage). Patients on preinjury ββ were excluded. Patients were stratified into (ββ+) and (ββ-) groups. Propensity score matching was performed (1:1 ratio) controlling for patient demographics, injury parameters and other medications that influence temperature. Outcomes were the number of febrile episodes, maximum temperature, and the time interval between febrile episodes. Multivariate linear regression was performed.
RESULTS
We analyzed 4,286 critically ill TBI patients. A matched cohort of 1,544 patients was obtained: 772 ββ + (metoprolol, 60%; propranolol, 25%; and atenolol, 15%) and 772 ββ-. Mean age was 63.4 ± 15.4 years, median head AIS score of 3 (3-4), and median Injury Severity Score of 10 (9-16). Patients in the ββ+ group had a lower number of febrile episodes (8 episodes vs. 12 episodes; p = 0.003), lower median maximum temperature (38.0°C vs. 38.5°C; p = 0.025), and a longer median time between febrile episodes (3 hours vs. 1 hour; p = 0.013). On linear regression, propranolol was found to be superior in terms of reducing the number of febrile episodes and the maximum temperature. However, there was no significant difference between the three ββ in terms of reducing the time interval between febrile episodes (p = 0.582).
CONCLUSION
Beta blockers attenuate PTH by decreasing the frequency of febrile episodes, increasing the time interval between febrile episodes, and reducing the maximum rise in temperature. ββ may be a potential therapeutic modality in PTH.
LEVEL OF EVIDENCE
Therapeutic, level IV.
Identifiants
pubmed: 33332783
doi: 10.1097/TA.0000000000002975
pii: 01586154-202101000-00023
doi:
Substances chimiques
Adrenergic beta-Antagonists
0
Atenolol
50VV3VW0TI
Propranolol
9Y8NXQ24VQ
Metoprolol
GEB06NHM23
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
177-184Informations de copyright
Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.
Références
Azim A, Joseph B. Traumatic brain injury. In: Surgical Critical Care Therapy . Springer; 2018:1–10.
Faul M, Wald MM, Xu L, Coronado VG. Traumatic brain injury in the United States; emergency department visits, hospitalizations, and deaths, 2002–2006. 2010.
Foks KA, Cnossen MC, Dippel DWJ, Maas AIR, Menon D, van der Naalt J, Steyerberg EW, Lingsma HF, Polinder S. Management of mild traumatic brain injury at the emergency department and hospital admission in Europe: a survey of 71 neurotrauma centers participating in the CENTER-TBI study. J Neurotrauma . 2017;34(17):2529–2535.
Hallman MR, Joffe AM. ICU management of traumatic brain injury. Curr Anesthesiol Rep . 2013;3(2):89–97.
Astarabadi M, Khurrum M, Asmar S, Bible L, Chehab M, Castanon L, Ditillo M, Douglas M, Joseph B. The impact of non-neurological organ dysfunction on outcomes in severe isolated traumatic brain injury. J Trauma Acute Care Surg . 2020;89(2):405–410.
Zygun DA, Kortbeek JB, Fick GH, Laupland KB, Doig CJ. Non-neurologic organ dysfunction in severe traumatic brain injury. Crit Care Med . 2005;33(3):654–660.
Heffernan DS, Inaba K, Arbabi S, Cotton BA. Sympathetic hyperactivity after traumatic brain injury and the role of beta-blocker therapy. J Trauma Acute Care Surg . 2010;69(6):1602–1609.
Asmar S, Lokhandwala A, Richards J, Bible L, Avila M, Castanon L, Ditillo M, Douglas M, Joseph B. The neuroprotective effect of quetiapine in critically-ill traumatic brain injury patients. J Trauma Acute Care Surg . 2020.
Mrozek S, Vardon F, Geeraerts T. Brain temperature: physiology and pathophysiology after brain injury. Anesthesiol Res Pract . 2012;2012:989487.
Carney N, Totten AM, O’Reilly C, Ullman JS, Hawryluk GWJ, Bell MJ, Bratton SL, Chesnut R, Harris OA, Kissoon N. Guidelines for the management of severe traumatic brain injury. Neurosurgery . 2017;80(1):6–15.
Frishman WH. Beta-Adrenergic blockers. Med Clin North Am . 1988;72(1):37–81.
Mark R. The Story of MIMIC. Secondary Analysis of Electronic Health Records . Springer; 2016:43–49.
Axelrod YK, Diringer MN. Temperature management in acute neurologic disorders. Neurol Clin . 2008;26(2):585–603.
Laupland KB. Fever in the critically ill medical patient. Crit Care Med . 2009;37(Suppl 7):S273–S278.
Childers MK, Rupright J, Smith DW. Post-traumatic hyperthermia in acute brain injury rehabilitation. Brain Inj . 1994;8(4):335–343.
Meyfroidt G, Baguley IJ, Menon DK. Paroxysmal sympathetic hyperactivity: the storm after acute brain injury. Lancet Neurol . 2017;16(9):721–729.
Kemp CD, Johnson JC, Riordan WP, Cotton BA. How we die: the impact of nonneurologic organ dysfunction after severe traumatic brain injury. Am Surg . 2008;74(9):866–872.
Alexander RW, Davis JN, Lefkowitz RJ. Direct identification and characterisation of β-adrenergic receptors in rat brain. Nature . 1975;258(5534):437–440.
MacKenzie ET, McCulloch J, Harper AM. Influence of endogenous norepinephrine on cerebral blood flow and metabolism. Am J Phys . 1976;231(2):489–494.
Shigemori M, Abe T, Aruga T, Ogawa T, Okudera H, Ono J, Onuma T, Katayama Y, Kawai N, Kawamata T. Guidelines for the management of severe head injury, 2nd edition guidelines from the guidelines committee on the management of severe head injury, the Japan Society of Neurotraumatology. Neurol Med Chir (Tokyo) . 2012;52(1):1–30.
Cairns CJ, Andrews PJ. Management of hyperthermia in traumatic brain injury. Curr Opin Crit Care . 2002;8(2):106–110.
Brooke MM, Patterson DR, Questad KA, Cardenas D, Farrel-Roberts L. The treatment of agitation during initial hospitalization after traumatic brain injury. Arch Phys Med Rehabil . 1992;73(10):917–921.
Greendyke RM, Kanter DR, Schuster DB, Verstreate S, Wootton J. Propranolol treatment of assaultive patients with organic brain disease: a double-blind crossover, placebo-controlled study. J Nerv Ment Dis . 1986;174:290–294.
Lemmer B, Winkler H, Ohm T, Fink M. Chronopharmacokinetics of beta-receptor blocking drugs of different lipophilicity (propranolol, metoprolol, sotalol, atenolol) in plasma and tissues after single and multiple dosing in the rat. Naunyn Schmiedeberg’s Arch Pharmacol . 1985;330(1):42–49.
Fernandez-Ortega JF, Baguley IJ, Gates TA, Garcia-Caballero M, Quesada-Garcia JG, Prieto-Palomino MA. Catecholamines and paroxysmal sympathetic hyperactivity after traumatic brain injury. J Neurotrauma . 2017;34(1):109–114.
Foundation BT. Guidelines for the Management of Severe Traumatic Brain Injury 4th Edition: Braintrauma.org ; 2016 [cited 2020 August 6]. Available from: https://braintrauma.org/uploads/03/12/Guidelines_for_Management_of_Severe_TBI_4th_Edition.pdf .
Ahl R, Thelin EP, Sjölin G, Bellander BM, Riddez L, Talving P, Mohseni S. β-Blocker after severe traumatic brain injury is associated with better long-term functional outcome: a matched case control study. Eur J Trauma Emerg Surg . 2017;43(6):783–789.
Mohseni S, Talving P, Thelin EP, Wallin G, Ljungqvist O, Riddez L. The effect of β-blockade on survival after isolated severe traumatic brain injury. World J Surg . 2015;39(8):2076–2083.
Chen Z, Tang L, Xu X, Wei X, Wen L, Xie Q. Therapeutic effect of beta-blocker in patients with traumatic brain injury: a systematic review and meta-analysis. J Crit Care . 2017;41:240–246.
Alali AS, Mukherjee K, McCredie VA, Golan E, Shah PS, Bardes JM, Hamblin SE, Haut ER, Jackson JC, Khwaja K. Beta-blockers and traumatic brain injury: a systematic review, meta-analysis, and Eastern Association for the Surgery of Trauma Guideline. Ann Surg . 2017;266(6):952–961.
Khalili H, Ahl R, Paydar S, Sjolin G, Cao Y, Fard H, Niakan A, Hanna K, Joseph B, Mohseni S. Beta-blocker therapy in severe traumatic brain injury: a prospective randomized controlled trial. World J Surg . 2020;44:1844–1853.
Mosenthal AC, Lavery RF, Addis M, Kaul S, Ross S, Marburger R, Deitch EA, Livingston DH. Isolated traumatic brain injury: age is an independent predictor of mortality and early outcome. J Trauma Acute Care Surg . 2002;52(5):907–911.
Ghajar J. Traumatic brain injury. Lancet . 2000;356(9233):923–929.